|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:antidote
|
gptkb:idarucizumab
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
6.5%
|
|
gptkbp:blackBoxWarning
|
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:CASNumber
|
211914-51-1
|
|
gptkbp:chemicalClass
|
benzamidine derivative
|
|
gptkbp:contraindication
|
active pathological bleeding
mechanical prosthetic heart valve
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasCYPInteraction
|
not significant
|
|
gptkbp:hasInChIKey
|
AOJJSUZBOXZQNB-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C34H41N7O5
|
|
gptkbp:hasSMILES
|
CC(C)N1C(=O)NC(C(=O)N(C2CC2)C3=CC=CC=C3)C1=O
|
|
gptkbp:hasUNII
|
2ZC8356YK9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB08865
|
|
gptkbp:indication
|
prevention of venous thromboembolism
prevention of systemic embolism
prevention of stroke in non-valvular atrial fibrillation
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:legalStatus
|
patented
Rx-only
|
|
gptkbp:manufacturer
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:mechanismOfAction
|
direct thrombin inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
627.74
|
|
gptkbp:name
|
gptkb:Dabigatran
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
gptkb:DB08865
148124
D08143
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
gastrointestinal upset
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:Dabigatran_etexilate
BIBR 953 ZW
|
|
gptkbp:target
|
gptkb:thrombin_(F2)
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:bfsParent
|
gptkb:Xalkori
gptkb:ponatinib
|
|
gptkbp:bfsLayer
|
7
|